An MVA vaccine overcomes tolerance to human p53 in mice and humans

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• The p53 protein is overexpressed in nearly 50% of malignancies, making it a promising target for cancer vaccines.
• Previous immunotherapy attempts targeting p53 have shown success in preclinical models but failed in clinical translation.
• Modified vaccinia virus Ankara (MVA) vaccines expressing p53 have previously stimulated p53-specific immunity and rejected tumors in murine models.

Purpose of the Study:

• To investigate the immunologic mechanisms of MVA vaccines expressing human p53.
• To evaluate the capacity of MVA expressing human p53 to overcome tolerance and reject human p53-expressing tumors.
• To utilize a murine model (Hupki mice) with a modified human p53 gene to explore p53-based cancer immunotherapy.

Main Methods:

• Hupki mice, a model with a modified human p53 gene, were immunized with MVA expressing human p53 (MVAp53).
• The study assessed the generation of p53-specific CD8(+) T cells post-immunization.
• Tumor rejection was evaluated using a highly aggressive murine mammary carcinoma cell line (4T1) transfected with human p53 (4T1p53).

Main Results:

• MVAp53 immunization in Hupki mice successfully generated p53-specific CD8(+) T cells.
• The MVAp53 vaccine led to the rejection of established 4T1p53 tumors.
• An overlapping peptide library of human p53 was used to evaluate an immunologic correlate of tumor protection and stimulate T cell responses in cancer patients.

Conclusions:

• MVAp53 demonstrates the potential to overcome immune tolerance to p53.
• This approach shows promise for developing effective cancer immunotherapies targeting p53.
• Further research may lead to clinical applications of MVAp53 in cancer treatment.